CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea · Delayed Price · Currency is KRW 8,590.00
-260.00 (-2.94%)
At close: Feb 13, 2026
CJ Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -28,314 | -32,838 | -22,913 | -34,913 | -19,272 | -8,763 |
Depreciation & Amortization | 4,079 | 4,321 | 5,146 | 3,900 | 1,562 | 1,051 |
Loss (Gain) From Sale of Assets | 386.95 | -10.89 | -8,718 | 366.99 | -10.43 | 89.96 |
Asset Writedown & Restructuring Costs | - | - | - | - | 170.67 | - |
Stock-Based Compensation | - | - | 141.5 | 543.83 | 555.76 | 133.93 |
Provision & Write-off of Bad Debts | - | - | - | - | 105.27 | - |
Other Operating Activities | 1,762 | 1,846 | 1,880 | 3,375 | 9,460 | 667.78 |
Change in Accounts Receivable | -46.05 | 88.9 | 142.18 | -70.3 | -191.24 | -3.25 |
Change in Inventory | 83.61 | 29.07 | -81.66 | 69.66 | -231.19 | -265.64 |
Change in Accounts Payable | -87.86 | 98.01 | -213.84 | 48.91 | -421.5 | 420.07 |
Change in Unearned Revenue | 47.45 | 28.67 | 119.84 | 211.49 | 53.71 | 31.82 |
Change in Other Net Operating Assets | -3,366 | -1,324 | -401.61 | 5,505 | -218.1 | -1,342 |
Operating Cash Flow | -25,454 | -27,760 | -24,899 | -20,963 | -8,437 | -7,978 |
Capital Expenditures | -156.93 | -377.59 | -4,924 | -4,145 | -952.65 | -12,018 |
Sale of Property, Plant & Equipment | 68.98 | 26.34 | 33,116 | 85.09 | 10.45 | - |
Cash Acquisitions | - | - | - | -6,239 | - | - |
Sale (Purchase) of Intangibles | 264.53 | -206.02 | -11,493 | -725.5 | -26.1 | -2.32 |
Sale (Purchase) of Real Estate | - | - | - | - | - | -13,973 |
Investment in Securities | -53,000 | -67,000 | 0.21 | 18,018 | 7,158 | -513.34 |
Other Investing Activities | - | - | -0 | 171.58 | 262.42 | -0 |
Investing Cash Flow | -52,823 | -67,557 | 16,699 | 7,165 | 6,453 | -26,506 |
Short-Term Debt Issued | - | 1,705 | 1,305 | 2,636 | - | - |
Long-Term Debt Issued | - | - | - | - | - | 41,996 |
Total Debt Issued | 1,082 | 1,705 | 1,305 | 2,636 | - | 41,996 |
Long-Term Debt Repaid | - | -1,864 | -23,077 | -1,414 | -22,768 | -476.63 |
Net Debt Issued (Repaid) | -742.25 | -159.04 | -21,772 | 1,222 | -22,768 | 41,519 |
Issuance of Common Stock | 39,970 | 39,970 | 44,977 | 50 | 73,479 | 826.53 |
Other Financing Activities | -352.35 | -311.73 | -260.87 | -280.02 | -0 | 0 |
Financing Cash Flow | 38,875 | 39,499 | 22,944 | 992.18 | 50,711 | 42,345 |
Foreign Exchange Rate Adjustments | -4.52 | 32.13 | 26.74 | 69.69 | 78.4 | 40.87 |
Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | 0 | - | - |
Net Cash Flow | -39,407 | -55,786 | 14,772 | -12,737 | 48,805 | 7,901 |
Free Cash Flow | -25,611 | -28,138 | -29,823 | -25,108 | -9,390 | -19,997 |
Free Cash Flow Margin | -758.67% | -811.70% | -534.93% | -616.19% | -215.22% | -376.48% |
Free Cash Flow Per Share | -2092.62 | -3033.88 | -4210.07 | -4271.74 | -2208.24 | -5179.37 |
Cash Interest Paid | 352.35 | 311.73 | 190.87 | 30.02 | 361.12 | 249.03 |
Cash Income Tax Paid | - | 70.74 | 1.48 | 141.56 | 5.3 | 31.88 |
Levered Free Cash Flow | -14,560 | -16,913 | -32,209 | -17,249 | -6,708 | -17,565 |
Unlevered Free Cash Flow | -14,215 | -16,546 | -31,633 | -15,522 | -3,603 | -16,551 |
Change in Working Capital | -3,368 | -1,079 | -435.09 | 5,765 | -1,008 | -1,159 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.